Previous 10 | Next 10 |
2024-03-12 16:05:59 ET More on Heron Therapeutics Heron Therapeutics Is Out Of Survival Mode Upcoming FDA Decision: Heron Therapeutics' ZYNRELEF SNDA Heron Therapeutics Gets Back On Track Heron Therapeutics Q4 2023 Earnings Preview Heron Therapeutics ...
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates PR Newswire 2023 oncology care franchise revenue was $107.9 million , exceeding full-year 2023 guidance ZYNRELEF ® achieved quarterly...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...
2024-03-11 17:35:46 ET More on Heron Therapeutics Heron Therapeutics Is Out Of Survival Mode Upcoming FDA Decision: Heron Therapeutics' ZYNRELEF SNDA Heron Therapeutics Gets Back On Track Heron Therapeutics rises on securing label expansion for pain therapy ...
2024-03-11 17:35:46 ET Major earnings expected after the bell on Tuesday include: Clover Health Investments, Corp. ( CLOV ) SurgePays ( SURG ) Heron Therapeutics ( HRTX ) Qifu Technology ( QFIN ) Veritone ( VERI ) Read the full article on Se...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 PR Newswire SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announc...
2024-02-17 01:54:45 ET Summary Heron Therapeutics has made progress in shoring up its balance sheet and cutting expenses, improving its financial position. Revenue growth remains a challenge. The expanded label for Zynrelef and the partnership with CrossLink could help acceler...
2024-01-24 09:37:29 ET A California-based %Biotech company is turning heads on Wednesday morning after it was announced that the company received FDA approval for the supplemental new drug application for %Zynrelef to include additional orthopedic and soft tissue procedures, accordi...
2024-01-24 06:28:18 ET Heron Therapeutics ( NASDAQ: HRTX ) shares rose over 7% premarket on Wednesday after the U.S Food and Drug Administration approved label expansion for the biotechnology company's postoperative pain management solution, Zynrelef (bupivacaine and meloxic...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 PR Newswire SAN DIEGO , April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the compa...
Shares of Nucor Corporation (NYSE:NUE) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financia...
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday. Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply duri...